Drug General Information |
Drug ID |
D0W8JE
|
Former ID |
DPR000134
|
Drug Name |
Depudecin
|
Synonyms |
(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9
|
Drug Type |
Small molecular drug
|
Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Preclinical |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C11H16O4
|
Canonical SMILES |
CC(C1C(O1)C=CC2C(O2)C(C=C)O)O
|
InChI |
1S/C11H16O4/c1-3-7(13)11-9(15-11)5-4-8-10(14-8)6(2)12/h3-13H,1H2,2H3/b5-4+/t6-,7-,8?,9+,10+,11+/m1/s1
|
InChIKey |
DLVJMFOLJOOWFS-LMSNBXBHSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
|
Target and Pathway |
Target(s) |
Histone deacetylase 1 |
Target Info |
Inhibitor |
[2],
[3]
|
KEGG Pathway
|
Cell cycle
|
Notch signaling pathway
|
Thyroid hormone signaling pathway
|
Huntington's disease
|
Amphetamine addiction
|
Alcoholism
|
Epstein-Barr virus infection
|
Pathways in cancer
|
Transcriptional misregulation in cancer
|
Viral carcinogenesis
|
MicroRNAs in cancer
|
Chronic myeloid leukemia
|
NetPath Pathway
|
TCR Signaling Pathway
|
PANTHER Pathway
|
Wnt signaling pathway
|
p53 pathway
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
Notch signaling pathway
|
E2F transcription factor network
|
Presenilin action in Notch and Wnt signaling
|
Signaling events mediated by HDAC Class I
|
Regulation of Telomerase
|
Glucocorticoid receptor regulatory network
|
Sumoylation by RanBP2 regulates transcriptional repression
|
Regulation of Androgen receptor activity
|
IL3-mediated signaling events
|
Validated nuclear estrogen receptor alpha network
|
Retinoic acid receptors-mediated signaling
|
Hedgehog signaling events mediated by Gli proteins
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
Validated targets of C-MYC transcriptional repression
|
Regulation of retinoblastoma protein
|
Notch-mediated HES/HEY network
|
Reactome
|
G0 and Early G1
|
p75NTR negatively regulates cell cycle via SC1
|
Formation of the beta-catenin:TCF transactivating complex
|
NOTCH1 Intracellular Domain Regulates Transcription
|
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
|
Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
|
HDACs deacetylate histones
|
Deactivation of the beta-catenin transactivating complex
|
NoRC negatively regulates rRNA expression
|
RNA Polymerase I Transcription Initiation
|
Factors involved in megakaryocyte development and platelet production
|
WikiPathways
|
SIDS Susceptibility Pathways
|
Notch Signaling Pathway
|
TGF beta Signaling Pathway
|
IL-6 signaling pathway
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
|
Notch Signaling Pathway
|
Retinoblastoma (RB) in Cancer
|
Neural Crest Differentiation
|
TWEAK Signaling Pathway
|
Integrated Breast Cancer Pathway
|
Signalling by NGF
|
RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
|
Mitotic G1-G1/S phases
|
Factors involved in megakaryocyte development and platelet production
|
Cell Cycle
|
Androgen receptor signaling pathway
|
References |
REF 1 | HDAC inhibitors repress the polycomb protein BMI1. Cell Cycle. 2010 Jul 15; 9(14): 2722-2730. |
---|
REF 2 | Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. |
---|
REF 3 | Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. |